Evidence for optimizing highly active antiretroviral treatment (HAART) in Kenya Dr. Washingtone Ochieng CNHR RCDG Fellow returning from Harvard University,

Slides:

Advertisements

Similar presentations

TB/HIV Research Priorities: TB Preventive Therapy.

Advertisements

Contribution of Economics to Operational Research for Evaluation of Scaling Up Access to HIV Care & Treatment in Developing Countries Presentation by Pr.

HIV treatment as prevention Stephen Kegg. 2 Learning Outcomes Overview of HIV management HIV transmission risks Current prevention strategies Which new.

The U.S. President’s Emergency Plan for AIDS Relief The Evolving HIV Prevention Strategy for IDUs in PEPFAR Amb. Eric Goosby US Global AIDS Coordinator.

Funding of Cohort Studies Diana Finzi, Ph.D. Chief, Pathogenesis and Basic Research Branch Division of AIDS National Institutes of Health Bethesda, Maryland,

Treatment challenges of 2 nd /3 rd line HIV/AIDS, hepatitis-C in Seychelles BY DR LOUINE MOREL.

Summary Slide Presentation Principles of HIV drug resistance for clinical management in South Africa Stott K, Michel J, de Oliveira T. Principles of HIV.

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

Potential role of PEP, PrEP and ART for HIV Prevention among Men who have Sex with Men Frits van Griensven, PhD, MPH Division of HIV/AIDS Prevention US.

HIV/AIDS and Substance Use Disorders Olivera J. Bogunovic, M.D. State University of New York at Buffalo Alcohol Medical Scholars Program.

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing.

Incorporating HIV and Viral Hepatitis Testing and Referral into Idaho Drug Court Programs Presented by Idaho Advisory Council on HIV and AIDS, Bebe Thompson,

Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.

The Namibia Treatment Literacy Approach: Empowering Patients with Knowledge on Antiretroviral Therapy Through Audiovisual Materials Authors Francis Kalemeera.

Tajikistan The Global Fund to Fight AIDS, Tuberculosis and Malaria Support to the Strategic Plan to Prevent HIV/AIDS Epidemics in Tajikistan. November.

Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.

Comprehensive HIV Prevention Strategies for Most at Risk Populations (MARPs) Anne Goldzier Thomas, Ph.D. US Department of Defense/PEPFAR Ethiopia National.

HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.

Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.

HIV Treatment and Care Research priorities Facilitator – Dr Saphonn Vonthanak 12 participants 29 agreed topics –not grouped on methodology or subject category.

RCGP training online: new training in short bites Danny Morris, Expert Lead RCGP Hepatitis B and C Part 1.

1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

1 HIV/AIDS Related Research Agenda Workshop Phnom Penh, Sunway Hotel March 28-29, 2007.

2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.

Summary Slide Presentation Are subtype differences important in HIV drug resistance? Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences.

Office of Overseas Programming & Training Support (OPATS) Treatment Adherence HIV Care, Support, and Treatment.

Missed opportunities to diagnose TB and HIV Co-infection in HIV workplace program Dr Fred Mugyenyi Asiimwe Medical Director, ALAFA.

I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.

Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.

Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.

The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.

ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.

Promoting Rational Use of ARVs in HIV/AIDS Clinics in Tanzania Presented by Salama Mwakisu -MSH.

Decline in incidence of HIV and Hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? 1. Julius Center, University.

Background Appropriate time to start HAART is still debatable 1995: “Time to hit HIV, early and hard” Eradication thought to be possible Early regimens.

Improving Appointment Keeping and Adherence Monitoring In ART Facilities in Kenya: Views of Providers and Patients Susan Njogo National AIDS/STI Control.

Dr Rochelle Adams ACC Project Manager On behalf of the ACC team AWACC November 2015 Health systems Strengthening for Success and Sustainability.

Integration of collaborative TB/HIV activities with harm reduction services Maryna Zelenskaya Ph D State service on HIV/AIDS and other socially diseases.

HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.

Monodisciplinary, Multidisciplinary, Interdisciplinary, and Transdisciplinary Approaches to Reproductive Health Research II William A. Fisher, Ph.D Department.

1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.

Antiretroviral treatment programme in Thyolo district, Malawi Southern Region. MSF Luxembourg & Thyolo District Health Services - Strategic information.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

1 Scaling-up ARV Therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.

GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.

Lessons Learned and Novel Investigation Techniques in Response to a Large Community Outbreak of HIV-1 infection Philip J. Peters MD HIV Testing and Biomedical.

Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.

ARV Treatment Scale Up: Progress in Ukraine Andriy Klepikov Executive Director, International HIV/AIDS Alliance in Ukraine ARV Treatment Scale Up: Progress.

Linkages between CDs & NCDs: The African context Dr Frank J Mwangemi ICASA 2011: 5 th December 2011 Addis Ababa, Ethiopia.

From Aggregate Indicators to Impacting Patients - Data Use to Inform Treatment and Improve Care Ian Wanyeki Track 1.0 Implementers Meeting Dar Es Salaam.

#AIDS2016 HOW TO LAUNCH PROGRAMMES FOR PEOPLE WHO USE SUBSTANCES AND ARE AFFECTED BY HIV ACROSS MORE GENERALIZED HIV EPIDEMIC SETTINGS.

Hepatitis C Consultation Services (844) | 9AM-5PM ET, M-F nccc.ucsf.edu The Clinician Consultation Center (CCC) provides up-to-date expert clinical.

Treatment as prevention: policy and programmatic considerations

Learning objectives Define HIV treatment goals

Pengjun Lu, PhD, MPH;1 Kathy Byrd, MD, MPH;2

Entry into care Failure to initiate timely HIV care after diagnosis is common ~75% of newly diagnosed link to care within 6-12 months Delayed entry into.

Zimbabwe’s shift towards treat all: national country context

Introduction Results Objectives Methods Conclusion Funding

Madisa Mine National Health Laboratory Gaborone, BOTSWANA

HIV Diagnosis and the Cascade of Care in Ontario

World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.

CommCare as a Tool to Reduce Loss to Follow Up

EVALUATION OF ANTIRETROVIRAL THERAPY FOLLOWED BY AN EDUCATIONAL INTERVENTION TO INCREASE APPROPRIATE USE IN ZIMBABWE.

Epidemiologic trends in HIV infection among men who have sex with men in Ontario: The situation in 2003 Robert S. Remis, Maraki Fikre Merid Ontario HIV.

Summary Sheet Figures and Maps

Summary Sheet Figures and Maps

Summary Sheet Figures and Maps

For a healthy Zambia.

HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE

Presentation transcript:

Evidence for optimizing highly active antiretroviral treatment (HAART) in Kenya Dr. Washingtone Ochieng CNHR RCDG Fellow returning from Harvard University, U.S.A Research Host: CREATES

Summary: HIV Prevalence & treatment Declining prevalence, rising numbers! Longevity- ART More PLWH TREATMENT ARV access improved Monitoring not so Adherence & failure Study sites

Relevance to Policy Great progress at controlling the HIV epidemic, but Exposure trends and sources are increasing Substance use, Commercial sex, same sex etc. Increased ARV access- likely to drive resistance and misuse Weak monitoring structures- need evidence-backed guidance

Treatment failure and underlying influencers Overall, 35.9% of all patients failed treatment Failure highest among Patients receiving D4T(stavudine) regimen First-line D4T discontinued elsewhere but still widely used in Kenya 33.3% of the patients developed resistance to major drugs in use Single viral load test is efficient for treatment failure definition

Patients active in peer support programs had good adherence Patient with good adherence had lower viral load Peer support improves adherence & treatment outcome * ** Adherence Peer Support * ** Viral load

HIV as a collection of sub-epidemics of many virus strains Observed increased diversity of HIV in the drug-target genes Identified HIV-1 subtype B, only common in Europe & the Americas Multiple strains complicate disease & treatment outcomes SUBTYPE/Strain % HIV diversity within in Envelope (vaccine target)Pol (drug target) A79 67 B 0 5 C014 D010 Recombinants215

Increased burden of infection among substance users. 66.2% injectors and 33.8% non-injectors HIV-1 prevalence; 87.5% among injectors. Hepatitis C prevalence; injectors (16.3%) & non-injectors (4.3%)

①Implement point-of-care viral load testing to monitor failure ②Implement patient-focused adherence support programs Strengthen patient-physician and patient-patient relationships ③Regularize drug toxicity testing- D4T regimen phase-out per WHO ④Institutionalize drug resistance testing (reference testing centers) ⑤Capacity building- train and impart relevant skills on testing Policy decision-points:

6). Public health approach to alleviate behavioral risks Substance replacement therapy; treatment-as-a-prevention Pre-exposure prophylaxis; Test-and-treat’; self-reporting support 7). Ministry of Health to partner with research groups to Support research activities that will enhance informed policy decisions Actively monitor disease epidemiology and genetics Policy decision-points-cont…

Summary HIV treatment access has improved- Monitoring needs scaling Patient Participation in adherence programs useful Drug/substance abuse compromising gains Policy decisions to intersect with Research evidence Other outcomes: Graduate & undergraduate trainings, publications, Conferences

Acknowledgement Centre for Research in Therapeutic Sciences (CREATES) Consortium for National Health Research (CNHR) for funding